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BACKGROUND & OBJECTIVES

PCN47
• Tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors are the standard of care for metastatic renal cell carcinoma (mRCC) [1] .
• Targeted therapies have greatly improved the prognosis of patients with mRCC [2] .
• However, real-world treatment patterns and their outcomes are not well characterized.
• The objectives of this study were to describe real world treatment patterns and to assess real world Progression Free Survival (PFS) in patients with mRCC.
METHODS
• Retrospective analyses using IMS RWD Oncology Cross-Sectional Survey Data, a longitudinal cancer treatment database collecting anonymized patient-level oncology data in 5 European countries.
• French patients with mRCC for whom data were collected between 2005 and 2015 were extracted.
• Analyses were performed on patients who received a first-line targeted therapy and for whom follow up data were available.
• Descriptive analyses were performed on treatment patterns and patient's characteristics.
• Kaplan-Meier curves were used to assess PFS.
• PFS was defined as a change of treatment due to local or distant progression.
Treatment sequences
RESULTS
CONCLUSION
• This study is the first analysis focused on describing real life PFS and treatment patterns in mRCC in France.
• Real life PFS was consistent with other published real life PFS data [3] .
• Treatment patterns observed in mRCC were consistent with clinical guidelines [4] .
• Treatment patterns and PFS should be interpreted with caution since data beyond the first line are available for 17% of patients. 
Patient's characteristics
• In patients with mRCC who received a first-line targeted therapy and for whom follow up data were available, the most frequent treatment sequences observed over a 10 year period were:
sunitinib-everolimus (24%), sunitinib-sorafenib (19%) and sunitinibaxitinib (7%). 
